Briacell Therapeutics Corp Stock Net Income
| BCT Stock | 5.88 0.02 0.34% |
As of the 31st of January, Briacell Therapeutics shows the Standard Deviation of 11.39, mean deviation of 6.85, and Risk Adjusted Performance of (0.05). Briacell Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Briacell Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Briacell Therapeutics' valuation are provided below:We have found one hundred twenty available fundamental signals for Briacell Therapeutics Corp, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Briacell Therapeutics' prevailing fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 31st of January 2026, Market Cap is likely to drop to about 4.7 M. In addition to that, Enterprise Value is likely to grow to about (6.8 M) This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -23.9 M | -22.7 M | |
| Net Loss | -23.7 M | -22.5 M | |
| Net Loss | -4.4 M | -4.7 M | |
| Net Loss | (77.63) | (81.51) | |
| Net Income Per E B T | 1.14 | 1.08 |
Briacell | Net Income |
Evaluating Briacell Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Briacell Therapeutics Corp's fundamental strength.
Latest Briacell Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Briacell Therapeutics Corp over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Briacell Therapeutics financial statement analysis. It represents the amount of money remaining after all of Briacell Therapeutics Corp operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Briacell Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Briacell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (26.56 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Briacell Net Income Regression Statistics
| Arithmetic Mean | (8,892,757) | |
| Geometric Mean | 1,057,509 | |
| Coefficient Of Variation | (145.90) | |
| Mean Deviation | 10,348,634 | |
| Median | (2,584,122) | |
| Standard Deviation | 12,974,600 | |
| Sample Variance | 168.3T | |
| Range | 37.9M | |
| R-Value | (0.71) | |
| Mean Square Error | 89.1T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (1,824,101) | |
| Total Sum of Squares | 2693.4T |
Briacell Net Income History
Briacell Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Briacell Therapeutics is extremely important. It helps to project a fair market value of Briacell Stock properly, considering its historical fundamentals such as Net Income. Since Briacell Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Briacell Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Briacell Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Briacell Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Briacell Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Briacell Therapeutics.
| 11/02/2025 |
| 01/31/2026 |
If you would invest 0.00 in Briacell Therapeutics on November 2, 2025 and sell it all today you would earn a total of 0.00 from holding Briacell Therapeutics Corp or generate 0.0% return on investment in Briacell Therapeutics over 90 days. Briacell Therapeutics is related to or competes with Resverlogix Corp, Perimeter Medical, and Microbix Biosystems. Briacell Therapeutics is entity of Canada More
Briacell Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Briacell Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Briacell Therapeutics Corp upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 98.76 | |||
| Value At Risk | (11.83) | |||
| Potential Upside | 13.73 |
Briacell Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Briacell Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Briacell Therapeutics' standard deviation. In reality, there are many statistical measures that can use Briacell Therapeutics historical prices to predict the future Briacell Therapeutics' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (1.12) | |||
| Total Risk Alpha | (1.82) | |||
| Treynor Ratio | (0.48) |
Briacell Therapeutics January 31, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.47) | |||
| Mean Deviation | 6.85 | |||
| Coefficient Of Variation | (1,135) | |||
| Standard Deviation | 11.39 | |||
| Variance | 129.73 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (1.12) | |||
| Total Risk Alpha | (1.82) | |||
| Treynor Ratio | (0.48) | |||
| Maximum Drawdown | 98.76 | |||
| Value At Risk | (11.83) | |||
| Potential Upside | 13.73 | |||
| Skewness | (0.57) | |||
| Kurtosis | 10.66 |
Briacell Therapeutics Backtested Returns
Briacell Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0513, which signifies that the company had a -0.0513 % return per unit of risk over the last 3 months. Briacell Therapeutics Corp exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Briacell Therapeutics' Risk Adjusted Performance of (0.05), standard deviation of 11.39, and Mean Deviation of 6.85 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.11, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Briacell Therapeutics will likely underperform. At this point, Briacell Therapeutics has a negative expected return of -0.6%. Please make sure to confirm Briacell Therapeutics' skewness, and the relationship between the total risk alpha and rate of daily change , to decide if Briacell Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.38 |
Poor reverse predictability
Briacell Therapeutics Corp has poor reverse predictability. Overlapping area represents the amount of predictability between Briacell Therapeutics time series from 2nd of November 2025 to 17th of December 2025 and 17th of December 2025 to 31st of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Briacell Therapeutics price movement. The serial correlation of -0.38 indicates that just about 38.0% of current Briacell Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.38 | |
| Spearman Rank Test | -0.04 | |
| Residual Average | 0.0 | |
| Price Variance | 7.3 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Briacell Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Briacell Therapeutics Corp reported net income of (26.56 Million). This is 107.78% lower than that of the Biotechnology sector and 137.91% lower than that of the Health Care industry. The net income for all Canada stocks is 104.65% higher than that of the company.
Briacell Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Briacell Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Briacell Therapeutics could also be used in its relative valuation, which is a method of valuing Briacell Therapeutics by comparing valuation metrics of similar companies.Briacell Therapeutics is currently under evaluation in net income category among its peers.
Briacell Fundamentals
| Return On Equity | -4.44 | ||||
| Return On Asset | -1.62 | ||||
| Current Valuation | 22.62 M | ||||
| Shares Outstanding | 6.21 M | ||||
| Shares Owned By Insiders | 0.70 % | ||||
| Shares Owned By Institutions | 12.70 % | ||||
| Number Of Shares Shorted | 9.44 K | ||||
| Price To Book | 2.68 X | ||||
| EBITDA | (36.63 M) | ||||
| Net Income | (26.56 M) | ||||
| Total Debt | 4.32 M | ||||
| Book Value Per Share | 7.17 X | ||||
| Cash Flow From Operations | (28.17 M) | ||||
| Short Ratio | 0.35 X | ||||
| Earnings Per Share | (46.04) X | ||||
| Target Price | 20.0 | ||||
| Beta | 1.91 | ||||
| Market Capitalization | 36.4 M | ||||
| Total Asset | 21.65 M | ||||
| Retained Earnings | (154.51 M) | ||||
| Working Capital | (3.81 M) | ||||
| Net Asset | 21.65 M |
About Briacell Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Briacell Therapeutics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Briacell Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Briacell Therapeutics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Briacell Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Briacell Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Briacell Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Briacell Stock
Moving against Briacell Stock
| 0.84 | CFW | Calfrac Well Services | PairCorr |
| 0.78 | LA | Los Andes Copper | PairCorr |
| 0.77 | SMD | Strategic Metals | PairCorr |
| 0.76 | TTE | TotalEnergies CDR | PairCorr |
| 0.75 | ECU | Element 29 Resources | PairCorr |
The ability to find closely correlated positions to Briacell Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Briacell Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Briacell Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Briacell Therapeutics Corp to buy it.
The correlation of Briacell Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Briacell Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Briacell Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Briacell Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Briacell Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.